Synovis Life Technologies — Merger or Acquisition (December 2011)
18 slides from Synovis Life Technologies's merger presentation, Dec 13, 2011
Slide 1: Synovis and Baxter: Saving and Sustaining Lives - Together
Baxter Confidential - For Internal Use Only 1 Baxter International Inc. Synovis and Baxter: Saving and Sustaining Lives - Together December 13, 2011
Slide 2: Our Discussion Today
Our Discussion Today Baxter Confidential - For Internal Use Only 2 • An Introduction to Baxter • Our Common Values • Strategic Fit • What Happens Next • Discussion and Q&A
Slide 3: What Synovis Stands For…
What Synovis Stands For… Baxter Confidential - For Internal Use Only 3 Trust, Mutual Respect, High Communication and a Spirit of Cooperation
Slide 4: What Baxter Stands For…
What Baxter Stands For… Baxter Confidential - For Internal Use Only 4 Saving and Sustaining Lives Worldwide
Slide 5: Introducing Baxter
Introducing Baxter Baxter Confidential - For Internal Use Only 5 Baxter is a global, diversified healthcare company applying innovative science to develop specialty therapeutics and medical products that save and sustain patients’ lives. Every day, our products and services help treat thousands of p
Slide 6: Global Healthcare Company
Global Healthcare Company Baxter Confidential - For Internal Use Only 6 • Approximately 48,000 employees in more than 60 countries • Manufacturing facilities in 27 countries • Products sold in more than 100 countries • More than half of sales and earnings come from outside the United States Baxter i
Slide 7: At Baxter…
At Baxter… Baxter Confidential - For Internal Use Only 7 • R ecognized and trusted worldwide • A preferred partner in improving the quality of and access to healthcare • An innovator in science and technology • Committed to quality and excellence • Focused on sustained financial strength • A rewardi
Slide 8: Baxter - Years Strong
Baxter - 80 Years Strong Baxter Confidential - For Internal Use Only 8 • Strong values-based culture; based in Midwest • Significant R&D investment • Passionate team with significant depth of talent and expertise • Extensive global presence and network • Global brand equity that is highly respected
Slide 9: Diversified Portfolio and Expertise
Diversified Portfolio and Expertise Baxter Confidential - For Internal Use Only 9 • Diversified healthcare model provides competitive advantage and enhances company’s ability to innovate • Broad portfolio of medical devices, biotechnology and pharmaceutical products and therapies • Diverse technolog
Slide 10: BioScience Business
BioScience Business Baxter Confidential - For Internal Use Only 10 2010 Sales: $5.7 billion Baxter has been working in specialty biologic therapies for 80 years, and is a market leader in the areas of blood-based disorders for hemophilia and biotherapeutics for immune deficiencies and other conditio
Slide 11: BioScience Business Product Offerings
BioScience Business Product Offerings Baxter Confidential - For Internal Use Only 11 BioScience produces recombinant and plasma-based therapies that are used to treat: • Hemophilia and other bleeding disorders • Immune disorders • Hypoalbuminemia and hypovolemia • Alpha-1 antitrypsin deficiency • Va
Slide 12: BioScience's Mission is Built Upon our Strengths as an Organization
BioScience’s Mission is Built Upon our Strengths as an Organization Baxter Confidential - For Internal Use Only 12 We deliver innovative specialty therapies through strong, global brands that improve patients’ lives
Slide 13: BioSurgery Franchise - Key Products
BioSurgery Franchise - Key Products Baxter Confidential - For Internal Use Only 13 FLOSEAL Gelfoam Plus TISSEEL Hemostasis (stop bleeding) Tissue Sealing Tissue Fixation COSEAL ACTIFUSE ARTISS Tissue Healing TACHOSIL
Slide 14: Baxter BioSurgery
Baxter BioSurgery Baxter Confidential - For Internal Use Only 14 • Strong growth and global presence • Commercial expertise • Investing for the future
Slide 15: Synovis Strengths
Synovis Strengths Baxter Confidential - For Internal Use Only 15 • Synovis has a solid business with 26-year track record • Synovis’ deep insights in biological material technology and surgical medical devices • Synovis’ product mix is complementary to Baxter’s commercial product line and technical
Slide 16: Questions?
Baxter Confidential - For Internal Use Only 16 Questions?
Slide 17: Proxy Information
Proxy Information Baxter Confidential - For Internal Use Only 17 In connection with the proposed acquisition and required shareholder approval, Synovis will file with the U.S. Securities and Exchange Commission (SEC) a proxy statement. The proxy statement will be mailed to the shareholders of Synovi
Slide 18: Safe Harbor
Safe Harbor This material includes forward-looking statements concerning a definitive agreement between Baxter International Inc. and Synovis Life Technologies, Inc. pursuant to which Baxter will acquire Synovis, including expectations with respect to the closing of the transaction and its financial
Synovis Life Technologies — Merger or Acquisition (December 2011) on 6ix